TATata MFGrowth

Tata Life Science & Technology Fund - Growth

Multi Cap FundEquity - Multi Cap FundBenchmark: NIFTY 500
NAV · 14 Sep 2012₹70.14-0.35%
AUM₹44 Cr
Expense Ratio2.50%
CAGR
Exit Load1% on or before 365D
Min SIP₹500
Launched1999

Investment Objective

The investment objective of the Scheme will be to provide income distribution and /or medium to long term capital gains while at all times emphasising the importance of capital appreciation.

Fund Mandate

Debt0%–20%
Equity80%–100%
MMI0%–20%
Others0%–20%
Asset Allocation
Domestic Equity99.1%
Cash & Equivalents0.9%
Fund Managers
BS
Bhupinder Sethi
Fund Manager
Key Information
2.50%
₹500
₹5,000
1% on or before 365D
Nil
Inception02 Jul 1999
AMCTata MF
Top Holdings
1Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)FMCG10.55%
2Zydus Lifesciences Ltd.Healthcare10.49%
3Nestle India Ltd.FMCG8.86%
4Wipro Ltd.IT8.42%
5Infosys Ltd.IT7.61%
6Sanofi India Ltd.Healthcare7.17%
7Pfizer Ltd.Healthcare6.74%
8Oracle Financial Services Software Ltd.IT5.07%
9Polaris Consulting & Services Ltd.IT4.48%
10Hinduja Global Solutions Ltd.IT4.37%
Sector Allocation
IT37.5%
Healthcare37.3%
FMCG19.4%
Telecom3.3%
Capital Goods1.6%
Others0.9%
Trailing Returns
PeriodReturns
1 Day-0.35%
Risk Metrics

Risk metrics are not available for this fund.

Fees
2.50%
1% on or before 365D
Nil
₹500
₹5,000
Capital Gains Tax, general rules

This is an equity-oriented fund. Under rules effective since Budget 2024 (23 July 2024):

Short-Term Capital Gains (held ≤ 12 months): taxed at a flat 20%.

Long-Term Capital Gains (held > 12 months): taxed at 12.5% on gains above ₹1.25 lakh in a financial year, with no indexation benefit.

General information only, not tax advice, actual liability depends on your overall income and applicable law at the time of redemption. Consult a tax advisor for your specific situation.

Frequently Asked QuestionsGeneral mutual-fund FAQs, not specific to this scheme